ZMI Pharma

ZMI Pharma is a private, commercial-stage biotech company founded in 2017 that has successfully brought a differentiated naloxone product to market. Its flagship product, ZIMHI, is a 5mg/0.5mL intramuscular naloxone injection, which it touts as the highest dose of naloxone available in an intramuscular auto-injector format. The company's strategy is centered on addressing the limitations of existing overdose rescue kits in the face of potent synthetic opioids like fentanyl by offering a rapid, high-dose alternative. ZMI Pharma appears to be a single-product company navigating the competitive and price-sensitive generic drug and overdose reversal market.

High-dose formulation and delivery device for established emergency rescue medication; focused on optimized pharmacokinetics (5mg intramuscular dose) and human-factor design for layperson use.

ZIMHI competes in the crowded opioid overdose reversal market against generic naloxone vials/syringes, the dominant nasal spray Narcan (4mg, Emergent BioSolutions), higher-dose generic nasal sprays (e.g., Kloxxado 8mg, Hikma), and other IM auto-injectors (Evzio, now discontinued). Competition is based on dose, delivery format, ease of use, price, and inclusion in treatment guidelines.